Emerging Therapies for Peanut Allergy.
J Pharm Pract
; 35(2): 289-297, 2022 Apr.
Article
en En
| MEDLINE
| ID: mdl-33148108
ABSTRACT
Peanut allergy (PA) is a food allergy that causes an IgE-mediated type I hypersensitivity reaction. PA has become an increasing public health burden, with 2% of American children reported to have this condition in 2010. Current guidelines recommend allergen avoidance, patient education, and administration of H1 antihistamines, ß2-agonists, or epinephrine based on the severity of reaction. In this review article, emerging therapies for PA are evaluated for their potential role in treating PA. Oral, epicutaneous, and sublingual immunotherapies have completed clinical trials with promising efficacy. In particular, Palforzia (AR101) is an oral immunotherapy that received Food and Drug Administration (FDA)-approval in January 2020 and Viaskin Peanut is an epicutaneous immunotherapy with an anticipated FDA decision date by August 5, 2020. Furthermore, adjuvant combinations with either probiotics or anti-IgE receptor antagonists have shown an improved efficacy and safety profile compared to oral immunotherapy alone. However, immunotherapy-induced adverse reaction rates are high due to the risks associated with intentional allergen exposure. These results suggest that peanut immunotherapy has a promising role in the treatment of PA, although further studies are needed before its incorporation into standard of care.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hipersensibilidad al Cacahuete
/
Hipersensibilidad a los Alimentos
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Child
/
Humans
Idioma:
En
Revista:
J Pharm Pract
Asunto de la revista:
FARMACIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos